Intas Enters into an Exclusive License Agreement with Meiji and Dong-A ST to commercialize DMB-3115 (Proposed Biosimilar to Ustekinumab)

0

Intas Pharmaceuticals Ltd continues to pledge their commitment to increasing access to high quality medications by entering into an unique license arrangement

AHMEDABAD, India, July 22, 2021/ PRNewswire/– Intas Pharmaceuticals Ltd continues to promise their commitment to increasing access to high quality medicines by participating in a special license contract with Meiji and Dong-A Socio Holdings (a parent business of Dong-A ST) to commercialize DMB-3115, a proposed biosimilar to ustekinumab, a recombinant monoclonal antibody for the treatment of autoimmune and inflammatory diseases such as plaque psoriasis, Crohn’s illness and ulcerative colitis.

Under the terms of the arrangement, Intas have been granted unique license rights to advertise DMB-3115 worldwide, leaving out Japan, Korea and particular nations in Asia. Meiji and Dong-A ST will manufacture and establish DMB-3115 and provide the product to Intas and its worldwide affiliates.

This is yet another market first for Intas, among the leaders in the development and commercialization of biosimilar items, who are the very first Indian company to introduce a biosimilar item in the EU.

“We are truly delighted by this partnership, which brings together the advancement know-how of Meiji and Dong-A ST with the comprehensive industrial reach of Intas,” said Vice Chairman, Mr. Binish Chudgar. “This agreement highlights our vision and dedication to increase access to life-altering medicines that can make a real difference to patient lives throughout the world,” said Chrys Kokino, President of Accord BioPharma, Inc., the US specialty subsidiary of Intas.

About Dong-A ST

Dong-An is among the leading pharmaceuticals in Korea. Dong-A has actually solidified its leading market position on the strength of in-house developed items such as Suganon tab. Evogliptin, the DPP-4 inhibitor for type 2 diabetes mellitus, Zydena tab. Udenafil, the fourth PDE5 inhibitor worldwide for impotence, Stillen tab. Eupatilin for organic treatment of gastritis and Motilitone tab. Corydaline for practical dyspepsia. Dong-An offers branded generic drugs (anti-cancer, anti-TB, and so on), bio-pharmaceutical, IMD, APIs and OTC items guaranteeing complete compliance with global quality standard. Currently Dong-A exports its products to more than 50 countries to leading pharmaceutical business in Europe, Latin America and Asia.

To learn more, please see http://en.donga-st.com.

About Meiji

Meiji is a leading pharmaceutical company in Japan in the healing locations of transmittable illness and central nervous system conditions. Considering that entering pharma industry with launch of penicillin in 1946, Meiji has been building up proprietary technologies on R&D and manufacture of small molecules as well as biotherapeutics and is supplying premium pharmaceutical items to clients in Japan and overseas. Meiji continues to accommodate client’s diverse medical requirements as a “Specialty and Generic Pharmaceuticals Company”.

For more details, please see

https://www.meiji.com/global/about-us/corporate-profile/meiji-seika-pharma/

About Intas

Intas Pharmaceuticals Ltd. is a leading vertically integrated pharmaceutical business based in Ahmedabad, India, having end-to-end capabilities of formulation development, production and marketing in addition to backward integration of APIs. Intas has more than 16,000 workers, sells products in more than 85 nations and has 14 manufacturing websites worldwide. The Intas group’s revenues totaled up to USD 2.1 bn in FY 2020 and the compounded yearly development rate of Intas’ revenues has actually surpassed 25% in the past 10 years.

To learn more, please see www.intaspharma.com
Intas Enters into an Exclusive License Agreement with Meiji and Dong-A ST to commercialize DMB-3115 (Proposed Biosimilar to Ustekinumab)

Comments

comments